PRG S&Tech is dedicated to developing innovative new drugs for rare diseases, with a focus on neurofibromatosis type 2 (NF2) and other genetic disorders.

Vision and Mission: Their mission is to lead the way in treating rare genetic diseases by advancing their robust pipeline of first-in-class drugs.

Noteworthy Points:

• Recently selected for the 2024 Bio and Medical Technology Development Project by the Ministry of Science and ICT.
• Commenced Phase 1.5 clinical trial for NF2 treatment.
• Published a significant protein research paper in the journal ‘Science’.